Pioneering molecular engineering technologies for systemic renewal
Harnessing the power of the body’s intercellular communication processes to trigger cellular repair and renewal
Precision therapeutics derived from engineered exosomes
Exosomes are nanoscale extracellular vesicles secreted by all cells to facilitate intercellular communication, naturally transporting proteins, lipids, and genetic material, to modulate gene expression and cellular behavior.
Highly tunable, cell-specific delivery leveraging the body’s intracellular communication channels equates to exceptional biocompatibility and low immunogenicity, offering promise for a range of precision medicine applications.
Harnessing the power of exosomes
Neucore is pioneering a proprietary platform of engineered fibroblast-derived extracellular vesicles to deliver therapeutic impact across areas of high unmet needs.
The unique regenerative biology of fibroblasts—cells central to tissue repair and structural integrity — enables restoration of function at the molecular level, offering a cost effective, scalable solution with curative potential.
Meet the Neucore Team
Kenneth L. Morand, Ph.D.
Co-founder and
Chief Executive Officer
Brian Price, Ph.D.
Co-founder /
Chief Scientific Officer /
Chief Technology Officer
Silvia Duarte-Sanmiguel, Ph.D.
R&D Director
Peter Kleinhenz
Co-founder /
Board chair
Michael Triplett, Ph.D.
Co-founder /
Board member
Daniel Gallego-Perez, Ph.D.
Scientific Co-founder
The Ohio State University
Natalia Higuita-Castro, Ph.D.
Scientific Co-founder
The Ohio State University
Neucore News
September 2, 2025
Neucore Bio Awarded U.S. National Institutes of Health (NIH) STTR Phase I Grant to Pursue Exosome-based Genetic Medicine for Charcot-Marie-Tooth Disease Type 1A (CMT1A)
August 06, 2025
Neucore Bio Awarded Competitive Grant from the U.S. National Science Foundation (NSF) for Research on Scalability of Exosome-based Therapeutics for Genetic Disease
Contact us
Neucore Bio, Inc.
2281 Kenny Rd,
Columbus Ohio 43210
info@neucorebio.com